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A B S T R A C T
Asfotase alfa is an enzyme replacement therapy approved for treatment of patients with pediatric-onset hypo-
phosphatasia (HPP), a rare, inherited, systemic disease causing impaired skeletal mineralization, short stature,
and reduced physical function in children. The role of dual X-ray absorptiometry (DXA) in the assessment of
children with HPP has been insufficiently explored. This post hoc analysis included pooled DXA data from 2
open-label, multicenter studies in 19 children with HPP. The study population was aged ≥5 to< 18 years and
had received asfotase alfa for ≤6.6 years at enrollment (male: 79%; median age at enrollment: 10.4 y [range:
5.9–16.7]; treatment duration: 6.3 y [range: 0.1–6.6]. Baseline height Z-scores indicated short stature (median
[min, max]: −1.26 [−6.6, 0]); mean [SD]: −2.30 [1.97]), thus requiring height adjustment of DXA Z-scores. At
Baseline, few patients had height-adjusted bone mineral density (BMDht) Z-scores of −2 or less for whole body
(n = 3) or lumbar spine (n = 5). In treated patients, mean whole body and lumbar spine BMDht Z-scores did not
change over time, but whole body and lumbar spine height- adjusted bone mineral content (BMCht) Z-scores
increased significantly from Baseline to Last Assessment (P ≤ 0.0056). Improvements in Radiographic Global
Impression of Change (RGI-C) scale scores correlated significantly with increases in whole body and lumbar
spine BMCht Z-scores (P < 0.05) but not BMDht Z-Scores. Improvements in Rickets Severity Score (RSS) cor-
related significantly with increases in lumbar spine BMDht Z-scores and whole body BMCht Z-scores (P < 0.05).
No significant correlations were observed between any DXA and bone histomorphometry measure. These
findings suggest that DXA BMD Z-scores, which are commonly used in clinical practice, have limited utility in
assessing deficient bone mineralization in patients with HPP. Although BMCht Z-scores increased significantly
over time with asfotase alfa therapy, the lack of significant changes in more than one DXA parameter suggests
that this tool may not be useful in everyday clinical practice. Furthermore, the use of BMC as an independent
metric is not typical or recommended by guidelines. Complementary measures, such as skeletal radiographs
supplemented with age-appropriate functional assessments, should be considered.
https://doi.org/10.1016/j.bone.2020.115413
Received 2 December 2019; Received in revised form 29 April 2020; Accepted 10 May 2020
⁎ Corresponding author at: Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, IIS La Princesa, Av. de Menéndez Pelayo, 65, 28009 Madrid,
Spain.
⁎⁎ Correspondence to: Department of Pediatrics, Vanderbilt University Medical Center, Vanderbilt University, Village at Vanderbilt, 1500 21st Ave South, Suite
1514, Nashville, TN, USA 37212
E-mail addresses: jill.h.simmons@vumc.org (J.H. Simmons), etrush@cmh.edu (E.T. Rush), Anna.Petryk@alexion.com (A. Petryk),
shanggen.zhou@covance.com (S. Zhou), gabrielangelmartos@yahoo.es (G.Á. Martos-Moreno).
Bone 137 (2020) 115413
Available online 14 May 2020




Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease
with systemic consequences caused by deficient tissue-nonspecific al-
kaline phosphatase (TNSALP) activity [1]. Lack of hydrolysis and ac-
cumulation of the TNSALP substrate inorganic pyrophosphate, a potent
mineralization inhibitor, leads to rickets and osteomalacia in children
with HPP. Other manifestations of HPP include pain, fractures, pre-
mature loss of teeth, short stature, craniosynostosis, joint stiffness,
muscle weakness, and reduced physical function such as compromised
ambulation [1–3].
Asfotase alfa (Strensiq®, Alexion Pharmaceuticals, Inc., Boston, MA,
USA) is the only human recombinant TNSALP enzyme replacement
therapy approved for treatment of patients of any age with pediatric-
onset HPP [4,5]. In children with HPP, improvements in skeletal
radiographic findings, growth, strength, motor function, pain, and
disability have been reported with asfotase treatment [6,7].
In clinical studies of asfotase alfa, changes in skeletal abnormalities
and mineralization defects were assessed using several modalities, in-
cluding skeletal radiographs, bone biopsies, and dual x-ray absorptio-
metry (DXA) [6,7]. Bone mineral density (BMD) measurements are
most commonly used in adults to diagnose osteopenia and osteoporosis
and to predict fracture risk, and DXA is also the preferred method to
assess bone density in children. Unlike in older adults, BMD in children
is expressed in Z-score instead of T-score [8–11]. However, the inter-
pretation of DXA measurements in children is limited by the potentially
misleading nature of areal (vs. volumetric density) BMD measurements;
impact of a growing skeleton on follow-up measurements; and lack of
clear consensus on how to adjust for variations in bone size, body
composition, growth impairment, and physiologic maturity [8,9].
Understanding of the correlation of BMD to fracture risk in a pe-
diatric population is poor [10]. As such, the utility of DXA in children
with HPP has been insufficiently explored and is also poorly under-
stood. This post hoc analysis of pooled data from 2 open-label, multi-
center studies of asfotase alfa [6,7] was conducted to understand the
utility of DXA as a diagnostic tool or as a means of measuring treatment
efficacy in children with HPP.
2. Methods
2.1. Study design
This is a post hoc analysis of pooled DXA data from children with
HPP from 2 open-label multicenter studies of asfotase alfa (Study 1:
study 006/008 [NCT00952484/NCT01203826; EudraCT number
2015–001128-52] [6]; Study 2: study 009 [NCT01163149; EudraCT
2017–001831-38] [7]) (Fig. 1). The study designs, key inclusion and
exclusion criteria, and primary and secondary outcome measures for
both studies have been published [6,7]. Briefly, patients eligible for this
analysis were ≥5 to<18 years of age at enrollment and had docu-
mented HPP-related rickets on skeletal radiographs (study 006/008)
and osteomalacia established by iliac crest biopsy (study 009). All pa-
tients were naïve to asfotase alfa therapy at the time of enrollment. In
study 006/008, patients were naïve to all bone-directed therapies, in-
cluding bisphosphonates. In study 009, patients treated with bispho-
sphates within 2 years of study entry or for> 2 years at any time were
excluded from enrollment. For patients from study 009 with prior bi-
sphosphonate use who were enrolled, bone resorption markers had to
be within normal range or elevated. Additionally, patients who received
treatment with parathyroid hormone within 6 months prior to treat-
ment with asfotase alfa were excluded from study 009. A negative result
of urine pregnancy testing was required before performance of DXA for
female patients of childbearing potential. Areal BMD was measured
using a Hologic scanner (Hologic, Inc., Marlborough, MA, USA) at the
study sites.
2.2. Study assessments
Assessments included change from Baseline in height-adjusted BMD
(BMDht) and bone mineral content (BMCht) Z-scores and absolute BMD
and BMC values for the whole body (including the head) and lumbar
spine as measured by DXA. DXA was performed at Baseline and ap-
proximately every 6 months thereafter. Z-scores were calculated using
methods and reference ranges described by Zemel et al. [12] A Z-score
of −2.0 or lower is considered low BMD relative to age in pediatric
patients [13]. Correlations between changes in DXA measures (both
BMD and BMC Z-scores and absolute values) and changes in radio-
graphic findings and bone histomorphometry assessments were eval-
uated. Assessments included (1) the Radiographic Global Impression of
Change (RGI-eC) scale [14], a 7-point scale ranging from −3 (severe
worsening of rickets) to +3 (complete or near-complete healing of
rickets); (2) Rickets Severity Score (RSS) [15], measured on a 10-point
scale (0 = absence of metaphyseal cupping and fraying to 10 = severe
rickets; maximum of 4 points for the wrists and 6 points for the knees)
that was originally developed to assess severity of nutritional rickets in
the wrists and knees; and (3) bone histomorphometry, which included
osteoid thickness, osteoid volume, and mineralization lag time. In study
006/008, bone biopsies for histomorphometry assessments were per-
formed at Baseline and Month 6. In study 009, bone biopsies were
performed at screening and Year 1 for patients randomized to asfotase
alfa and at screening and Month 6 for patients initially randomized to
the control group; study 009 patients initially in the control group were
excluded from the bone histomorphometry correlations in this analysis.
2.3. Statistical analysis
Changes from Baseline in DXA assessments were evaluated using
descriptive statistics, and P values were based on the Wilcoxon signed-
rank test comparing with 0. For correlation between changes in DXA
measures and changes in radiographic/bone histomorphometry as-
sessments, Pearson's correlation coefficients (PCCs [r]) were calculated,
with only the first and last overall measurements post-Baseline included
in the calculation. Baseline for all patients was defined as the last as-
sessment before the first dose of asfotase alfa.
3. Results
3.1. Patients
A total of 19 children (15 males and 4 females) with HPP were in-
cluded in the analysis (13 from study 006/008 and 6 from study 009).
Patient characteristics and asfotase alfa treatment exposure are shown
in Table 1. The median age at enrollment was 10.4 years (range:
5.9–16.7); 74% of patients were prepubertal. The median asfotase alfa
treatment duration was 6.3 years (range: 0.1–6.6).
3.2. Growth
Baseline height Z-scores reflected a trend toward short stature
(mean [SD]: −2.30 [1.97]; median [min, max]: −1.26 [−6.6, 0]),
necessitating height adjustment of DXA Z-scores. Median (min, max)
change from baseline in height Z-score at Last Assessment was 0.31
(−0.9, 1.9; P = 0.0047). Baseline weight Z-score was −1.06 (−8.2,
2.3), with a change of 0.74 (−4.9, 3.4; P= 0.0385) at Last Assessment.
3.3. DXA measures
At Baseline, only a minority of patients had whole body and lumbar
spine BMDht Z-scores of −2 or lower (17% [n = 3/18] and 28%
[n = 5/18] of patients, respectively).
Mean whole body or lumbar spine BMDht Z-scores did not change
during treatment with asfotase alfa; however, whole body and lumbar
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spine BMCht Z-scores increased significantly from Baseline to Last
Assessment (P ≤ 0.0056; Fig. 2). Absolute BMD and BMC values (mean
[95% CI]) for whole body and lumbar spine also increased during
treatment with asfotase alfa vs. Baseline, with significant increases at
Last Assessment (P < 0.0001) (Fig. 3). Individual BMD data (absolute
BMD values and BMDht Z-scores) over time are shown in Supplemental
Fig. 1.
Correlations between DXA and other skeletal parameters (RGI-eC,
RSS, and bone histomorphometric assessments) were calculated to
understand how well DXA compared with other assessments in mea-
suring skeletal changes in HPP. Improvements in RGI-C scale scores
correlated significantly with increases in whole body (P = 0.0001) and
lumbar spine (P = 0.0147) BMCht Z-scores but not BMDht Z-Scores
(Fig. 4; Supplemental Table 1). Correlations between improvements in
RGI-C scale scores and increases in whole body and lumbar spine BMD
and BMC absolute values were significant (all P < 0.001). Improve-
ments in the RSS correlated significantly with increases in whole body
BMCht Z-scores (P = 0.0140) and lumbar spine BMDht Z-scores
(P = 0.0225) (Fig. 4; Supplemental Table 1). Improvements in the
RSS were also significantly correlated with increases in lumbar spine
BMD absolute values (P = 0.0223); however, no significant correla-
tions with any other changes in absolute values of DXA measures was
observed. No significant correlations were observed between any DXA
measure and osteoid thickness (r = −0.348 to −0.179), osteoid vo-
lume (r =−0.398 to 0.065), or mineralization lag time (r =−0.115 to
0.006).
4. Discussion
This post hoc analysis of pooled data from 2 studies of asfotase alfa
assessed the potential utility of DXA as an instrument to measure de-
ficient bone mineralization in children with HPP. Baseline whole body
and lumbar spine BMDht Z-scores were not uniformly low (−2 or lower)
in children with HPP, and few patients with clear evidence of rickets on
radiograph or osteomalacia by bone biopsy had low BMD Z-scores.
Absolute values for BMD increased over time with asfotase alfa therapy;
however, BMDht Z-scores did not change. Absolute BMC values and
BMCht Z-scores increased with asfotase alfa therapy.
BMD Z-scores within a normal range have been previously reported
in both children and adults with HPP [2,16–20]. In a retrospective re-
view of data from 13 treatment-naïve children with HPP [18], whole
body and lumbar spine BMD Z-scores were within the normal range,
despite substantial reduction in functional exercise capacity (assessed
by the 6-Minute Walk Test, which was recently validated for physical
functional performance in patients with HPP [21]). In HPP, which is
Fig. 1. Study Design. aDose changes permitted for safety or efficacy concerns. b6-month primary treatment period: 6 or 9 mg/kg/wk.; extension phase: 3 mg/kg/wk.
for 3 to 9 months, then increased by protocol amendment to 6 mg/kg/wk. c6-month primary treatment period: 2.1 or 3.5 mg/kg/wk. or no treatment (control);
extension phase: 3.5 mg/kg/wk. for ~6 months to 1 year, then increased by protocol amendment to 6 mg/kg/wk.
Table 1
Patient characteristics and asfotase alfa exposure.
Variable All Patients (N = 19)
Age at enrollment, median (min, max), y 10.4 (5.9, 16.7)
Age at onset of HPP clinical manifestations, median
(min, max), y
0.5 (0.0, 1.8)
Race, white, n (%) 17 (89.5)
Sex, female, n (%) 4 (21.1)
Weight Z-score
Median (min, max) −1.06 (−8.2, 2.3)
Mean (SD) −1.57 (2.26)
Height Z-score
Median (min, max) −1.26 (−6.6, 0.0)
Mean (SD) −2.30 (1.97)
Asfotase alfa treatment duration, median (min, max), y 6.3 (0.1, 6.6)⁎
Asfotase alfa weekly total dose, median (min, max), mg/
kg
5.7 (2.1, 8.4)
⁎ All patients received treatment for> 2 years, with the exception of 1 pa-
tient who had a treatment duration of 1 month. No post-Baseline DXA data were
collected for this patient, and as such, this patient is excluded from the analyses
of change from baseline for DXA parameters.
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characterized by impaired mineralization, a treatment such as asfotase
alfa, which promotes mineralization, would be expected to increase the
BMCht Z-score, while the lack of increase in BMDht Z-score could be due
to the inability of DXA to properly discriminate between osteoid and
mineralized bone. Additionally, as DXA assesses areal bone density, not
volumetric bone density, a corresponding increase in the area involved
may also explain increased BMCht Z-score with sustained BMDhtZ-score.
Lastly, significant increases from baseline in growth (both height and
weight Z-scores) were observed at Last Assessment, which could also
explain the increase in BMCht Z-score but not in BMDht Z-score.
None of the DXA measures correlated with changes in bone histo-
morphometry (osteoid thickness, osteoid volume, or mineralization lag
time), which is the gold standard for the assessment of bone miner-
alization [22]. Increases in whole body and lumbar spine BMCht Z-
scores but not BMDht Z-Scores correlated with improvements in RGI-C
scale scores. The RGI-C scale evaluates several key radiographic
Fig. 2. Mean Change (95% CI) from Baseline in Height-Adjusted Z-scores for Bone Mineral Density (A: Whole Body*; B: Lumbar Spine) and Bone Mineral Content (C:
Whole Body; D: Lumbar Spine). *Data for whole body BMD Z-scores are not available at the Week 24 visit. BMCht = height-adjusted bone mineral content;
BMDht = height-adjusted bone mineral density.
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features of HPP, including metaphyseal flaring, fraying, radiolucencies,
physeal widening, metadiaphyseal sclerosis, thin ribs, chest deformity,
gracile bones, and evidence of recent fractures [14]. Increases in whole
body but not lumbar spine BMCht Z-scores correlated with changes in
RSS, and a correlation also was observed between increases in lumbar
spine BMDht Z-score and improvement in the RSS. The lack of corre-
lation between DXA measures and skeletal and bone histomorphometry
assessments in this analysis indicates that DXA does not measure re-
levant parameters that are critical to understanding bone health in
children with HPP (e.g., osteoid indices measured by bone biopsies,
pathognomonic changes revealed by skeletal radiographs) [23], un-
derscoring the limitations of DXA in this patient population. A recent
case report of an adult with HPP treated with asfotase alfa suggests that
other tools, such as high-resolution peripheral quantitative computed
tomography (HR-pQCT), may be useful in assessing improvement in
bone mineralization and quality indices beyond the bone mass mea-
sured by DXA [24]. However, evidence supporting the use of HR-pQCT
is currently limited, as HR-pQCT is not yet clinically available. In
Fig. 2. (continued)
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addition, normative data for HR-pQCT measures in children are
lacking, and use of this tool in children is associated with inherent
challenges, such as the need for patients to remain stationary for the
duration of the scan [25].
Collectively, the results of this analysis suggest that DXA measures
are of limited utility in the diagnosis of HPP, assessment of disease
severity, and determination of treatment efficacy. Although BMCht Z-
scores increased significantly over time with asfotase alfa therapy, the
use of BMC as an independent metric is not typical or recommended in
International Society for Clinical Densitometry guidelines [11].
Additionally, whereas DXA measurements are recommended for the
assessment of bone health in adults with osteomalacia or osteoporosis
and in pediatric patients with diseases that affect the skeleton [11,13],
previous data also suggest that DXA may not adequately measure ske-
letal abnormalities observed in patients with HPP [26]. A histomor-
phometric analysis of iliac crest biopsy samples from adults with HPP
found increased trabecular number, decreased trabecular separation,
increased osteoblast number and surface, and lower calcium content in
patients with HPP compared with healthy controls or individuals with
other types of osteomalacia [26]. It must be taken into consideration
Fig. 3. Mean (95% CI) Change from Baseline in Absolute Values for Bone Mineral Density (A: Whole Body; B: Lumbar Spine) and Bone Mineral Content (C: Whole
Body; D: Lumbar Spine). BMC = bone mineral content; BMD = bone mineral density.
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that the use of DXA in patients with HPP may be confounded by
aberrant density readings, potentially as a result of increased protei-
naceous components of nonmineralized bones or distorted bone trabe-
culation with areas of decreased mineralization and areas of local hy-
permineralization (sclerosis) [7,23,27]. Given these limitations, use of
skeletal radiographs supplemented with age-appropriate functional
assessments may be most useful in this patient population for assessing
disease progression and/or treatment efficacy. In clinical studies,
functional assessments of walking ability, gross motor function, func-
tional disability, and pain showed impairments at Baseline that im-
proved with asfotase alfa treatment over time [6,7]. It should be noted
that while radiographs can allow for the detection of rickets, defor-
mities, and fractures, there have been instances in adults with HPP
where abnormalities detected on computed tomography scans were not
readily apparent on radiographs [28]. Further, although the RSS is a
metric that has been used successfully in assessing the severity of
rickets [15], it is used inconsistently in clinical practice. The RGI-C was
developed for and is validated in HPP [14], and as such, we view this as
appropriate for assessing progression of disease in a controlled study.
We acknowledge that both the RSS and RGI-C are observer-dependent
and may not be ideal for use by all providers in daily clinical practice
and that both scales would be useful only if patients have obvious
Fig. 3. (continued)
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radiographic signs of rickets and open growth plates. The lack of ade-
quate, noninvasive tools to assess bone pathology in HPP beyond the
RGI-C remains a major gap and a limitation in clinical practice.
As this was a post hoc analysis, these study results have limitations.
As is common in clinical studies of rare diseases, the analysis population
was small and had a wide age range and a limited number of female
patients. As a result of the small sample size, large variability was ob-
served for some assessments, and small changes in BMD Z-score that
Fig. 4. Correlation of RGI-C scale scores and Change in RSS with Changes in Z-scores for Height-Adjusted Bone Mineral Density (A and B)* and Bone Mineral Content
(C and D). “r” Values provided are Pearson's correlation coefficients (only first and last overall measurements postbaseline are included in the calculation). The RGI-C
is a 7-point scale that ranges from −3 (severe worsening) to +3 (complete/near-complete healing) used to assess radiographic changes from Baseline in the most
common skeletal characteristics of HPP [14]. The RSS is 10-point scale (0 = absence of metaphyseal cupping and fraying [both characteristic of rickets] to
10 = severe rickets; maximum of 4 points for the wrists and 6 points for the knees) originally developed to assess severity of nutritional rickets in the wrists and knees
[15]. *Data for whole body BMD Z-scores are not available at the Week 24 visit. BMCht = height-adjusted bone mineral content; BMDht = height-adjusted bone
mineral density; RGI-C = Radiographic Global Impression of Change; RSS = Rickets Severity Score.
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could still be indicative of response to therapy would likely not be
detected. There was no cross-calibration of DXA scanners between
participating centers; to mitigate this limitation, comparisons were
made to the patient's own Baseline assessments. The whole body scan
included the head, which may have overestimated BMD in younger
patients. The relative contributions of asfotase alfa to the observed
improvements in DXA measures versus perceived improvements due to
growth-related changes in BMD are unclear. Additionally, in osteo-
porosis and other diseases, DXA is commonly used to evaluate and
predict fracture risk by considering BMD. According to the results we
have shown, and considering the phenotypic variability of the disease,
the utility of DXA for fracture prediction in HPP has not been estab-
lished. However, the detailed analysis of sequential evolution of other
parameters measured in DXA (such as BMC) could provide some in-
formation about disease progression or asfotase alfa treatment effect.
Since this study was based on data from the clinical trials and the study
population was limited, it would be interesting to see in future in-
vestigations if similar observations regarding DXA measurements
Fig. 4. (continued)
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before and after treatment with asfotase alfa would be made in a larger
cohort of pediatric patients in a more typical clinical setting.
5. Conclusion
Based on the data from this pooled post hoc analysis, DXA BMD Z-
scores, which are commonly used in clinical practice, are not a useful
measure of bone deficits in children with HPP, either for diagnosis or
monitoring treatment efficacy. Other complementary measures, in-
cluding skeletal radiographs and age-appropriate functional assess-
ments, should be considered.
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